Skip to main content
Clinical Trials/NCT01116349
NCT01116349
Terminated
Not Applicable

Diaphyseal Fractures of the Humerus: A Prospective Cohort Study Comparing the Conservative Treatment and the Surgical Treatment.

Hopital de l'Enfant-Jesus2 sites in 1 country4 target enrollmentJanuary 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Humeral Diaphysis Fracture
Sponsor
Hopital de l'Enfant-Jesus
Enrollment
4
Locations
2
Primary Endpoint
Function and quality of life on DASH scale
Status
Terminated
Last Updated
13 years ago

Overview

Brief Summary

The fracture of the humeral diaphysis is a condition that represents 2% of all fractures. The conservative treatment of diaphyseal fractures of the humerus has long been considered the only option and the surgical treatment was primarily reserved for displaced fractures with no contact of bone ends. However, for a few years there has been an upsurge of indications for the surgical treatment of diaphyseal fractures.

The purpose of this study is to compare the functional outcomes and the quality of life of surgically treated patients versus those who undergo a conservative treatment.

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
July 2014
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hopital de l'Enfant-Jesus
Responsible Party
Principal Investigator
Principal Investigator

Pelet Stephane

Dr Stephane Pelet MD, PhD Orthopedic surgeon

Hopital de l'Enfant-Jesus

Eligibility Criteria

Inclusion Criteria

  • Male or female over 18 years
  • Fracture of the humeral diaphysis
  • Recent fracture (14 days or less)
  • Closed fracture
  • Signing of consent form

Exclusion Criteria

  • Segmental fracture of the humerus
  • Fracture with proximal or distal intra articular extension
  • Open fracture
  • Polytrauma
  • Floating elbow or shoulder
  • Pathological fracture
  • Simultaneous fracture of both humerus
  • Associated vascular disease
  • Severe neuromuscular disorders such as Parkinson, hemiparesis, myasthenia gravis, muscular dystrophy, etc. ...
  • medical contraindication to surgery

Outcomes

Primary Outcomes

Function and quality of life on DASH scale

Time Frame: 6 months after treatment

The function and quality of life are measured using the DASH scale six months after treatment.

Secondary Outcomes

  • DASH score(12 months after treatment)
  • Return to professional activities(3 months after treatment)
  • SF-36 score(12 months after treatment)
  • Proportion of additional surgeries(12 months after surgery)
  • Radiological loss of reduction(6 months after treatment)
  • Union rate(6 months after treatment)
  • Rates of complication(within the first year following treatment)
  • Pain on visual analogue pain scale (VAS)(2 weeks after treatment)
  • Pain on VAS(12 months after treatment)
  • Measurement of range of motion of the shoulder(12 months after treatment)
  • Measurement of range of motion of the elbow(12 months after treatment)

Study Sites (2)

Loading locations...

Similar Trials